Universal Electronics Inc. to Provide Voice-Enabled Remotes for Liberty Global’s New Environmentally Friendly Set-Top Box
7.10.2020 22:10:00 EEST | Business Wire | Press release
Universal Electronics Inc. (UEI), the global leader in universal control and sensing technologies for the smart home, has been selected to provide voice-enabled remote control units to Liberty Global, one of the world’s leading converged video, broadband and communication companies with 11 million customers in six European countries, for its new environmentally friendly set-top box.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005930/en/
Universal Electronics Inc. to Provide Voice-Enabled Remotes for Liberty Global’s New Environmentally Friendly Set-Top Box (Photo: Business Wire)
The BLE voice-enabled remote control is powered by UEI chip technology, which enables longer battery life, with automated setup and control through UEI’s QuickSet® platform, which provides an unmatched cloud-based solution for simplifying universal entertainment and smart home control.
The remote is designed to improve the customer experience by using voice recognition technology to search for content on Liberty Global’s RDK-based Horizon 4 platform which offers access to live TV, on-demand content and OTT apps.
In August 2020, Liberty Global introduced the compact 4K Mini TV Box, which is made from 35% recycled plastic and reduces energy consumption by 77% compared to its previous set-top boxes. The 4K Mini TV Box, the company’s first all-IP device, is powered by Liberty Global’s next generation TV platform, Horizon 4.
The 4K Mini TV Box is currently available for customers of Liberty’s UPC Poland, the country’s largest cable provider. The set-top box will be introduced in Liberty Global’s other markets in 2021.
“We have a solid and collaborative relationship with UEI with a shared commitment to quality and sustainability,” said Pieter Vervoort, Vice President, Entertainment Products at Liberty Global.
UEI has implemented several sustainability initiatives in its development, supply chain and manufacturing processes, including remanufacturing remote controls, using recycled materials and developing more energy efficient products.
“We are pleased and proud to be selected for this project as it allows us to be at our best, providing an extremely easy-to-use control solution in a durable, sustainable way,” said Menno Koopmans, UEI’s Senior Vice President of Global Sales and Marketing. “Building upon our long-term partnership, we are thrilled to deliver another piece of cutting-edge, voice-enabled control technology to Liberty Global.”
UEI has been at the forefront of developing entertainment and smart home control technologies for over three decades. UEI was the first to introduce voice control and advanced features such as automated setup and universal control of connected devices through its QuickSet platform. Since 2015, UEI has shipped over 100 million of its voice-enabled remote controls to customers around the world.
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in universal control and sensing technologies for the smart home. The company designs, develops, manufactures and ships over 500 innovative products that are used by the world’s leading brands in the consumer electronics, subscription broadcast, security, home automation, hospitality and climate control markets. For more information, please visit www.uei.com.
All trademarks appearing herein are the property of their respective owners.
QuickSet is a trademark of Universal Electronics Inc.
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release including the BLE voice enabled remote control, and UEI’s proprietary chip and QuickSet technologies; the continued penetration and growth of the Liberty Global Horizon 4 platform and 4K Mini TV Box, and other products and consumer technologies identified in this release; and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005930/en/
Contact information
Shoshana Leon
Corporate Communications
Universal Electronics Inc.
sleon@uei.com
+1 480-521-3354
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom